Your Voice Your Vote 2024

Live results
Updated: Nov. 10, 11:43 PM ET

National Election Results: presidential

republicans icon Projection: Trump is President-elect
226
312
226
312
Harris
71,145,751
270 to win
Trump
74,673,847
Expected vote reporting: 94%

Infant Goes Into Remission Thanks to Cancer Treatment Breakthrough With 'Edited' Cells

Immune cells were "edited" by scientists so that could attack her cancer.

ByABC News
November 6, 2015, 4:26 PM

— -- A breakthrough technology has given hope to a family who thought their baby daughter may not survive to her second birthday.

Layla Richards was diagnosed with leukemia last year at 14 weeks old, according to the Great Ormond Street Hospital in London. While her doctors tried multiple treatments, including a bone marrow transplant, nothing worked for the girl.

Just after her first birthday, doctors suggested Layla’s family consider palliative care.

“We didn’t want to accept palliative care and give up on our daughter, though, so we asked the doctors to try anything,” Lisa Richards said on the hospital website.

Hospital officials then offered the family one shot at an experimental treatment that had only been tried before in mice. The medical staff would retrain donated T-cells, which help fight off infection in the body, in the hopes that they would attack her cancer. Using these kinds of “edited” T-cells from a donor had never been tried before.

Calls to the Great Ormond Street Hospital seeking additional comment from Layla's family or medical team were not immediately returned.

Dr. Waseem Qasim, professor of cell and gene therapy at University College of London’s Institute of Child Health , worked with the family and helped design Layla’s treatment. Because Layla didn’t have enough T-cells of her own to donate and be modified with genetic material, doctors had to use donated cells

Using tools that act like genetic “scissors,” the doctors were able to cut genes from the modified donor T-cells so that they would not attack her and cause a dangerous “graft vs. host” condition. They used the same tools to add synthetic genetic material that made the cells go after the cancer.

“The approach was looking incredibly successful in laboratory studies, and so when I heard there were no options left for treating this child’s disease, I thought, ‘Why don’t we use the new [modified T-cells]?” Qasim said on the hospital website.

Once prepared, it was as simple as giving Layla an injection, and while a severe immune response was possible, the girl only developed a rash.

Weeks later the doctors called in Lisa Richards and gave her the results.

"I thought it was bad news but then he said, ‘It’s worked’ and I just cried happy tears,” Lisa Richards said on the hospital website.

Layla went into remission and eventually had a second bone marrow transplant to build up her immune system. She’s now home and, seemingly, healthy with her family.

Layla's doctors are excited by her progress but said they need to replicate the findings.

“We have only used this treatment on one very strong little girl, and we have to be cautious about claiming that this will be a suitable treatment option for all children,” Dr. Qasim said. “But this is a landmark in the use of new gene engineering technology and the effects for this child have been staggering.

"If replicated, it could represent a huge step forward in treating leukemia and other cancers."

Experts say this case could be the start of a new frontier in fighting cancer. While similar treatments called immunotherapy are being studied globally, this is the first case where a donor T-cell was modified to fight cancer in a patient. In other treatments, the patient's T-cells are generally withdrawn, modified and then injected.

“It opens up the next set of options where you could in theory have these [prepared t- cells] ready for leukemia” treatment, said Dr. Madan Jagasia, Outpatient Stem Cell Transplant Program at Vanderbilt-Ingram Cancer Center. “What’s happening [now] is you’re wasting several weeks to reprogram T-cells” from the original patient.